UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE

Chest, 2016-11, Vol.150 (5), p.1059-1068

2016

Volltextzugriff (PDF)

Abstract 18238: Transition from Vitamin-K-antagonists to New Oral Anticoagulants in Daily Care - First Results of the Prospective NOAC Registry (NCT 01588119)

Circulation (New York, N.Y.), 2012-11, Vol.126 (suppl_21)

2012

Volltextzugriff (PDF)

Anticoagulant therapy for splanchnic vein thrombosis

Journal of thrombosis and haemostasis, 2020-07, Vol.18 (7), p.1562-1568

2020

Volltextzugriff (PDF)

Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

Stroke (1970), 2022-02, Vol.53 (2), p.532-543

2022

Volltextzugriff (PDF)

579 The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S332-S333

2019

Volltextzugriff (PDF)

Abstract 13927: Advanced Age and Preferential Use of Vitamin K Antagonists in Severe Renal Impairment: First Results of the XARENO Registry in Patients With Non-valvular Atrial Fibrillation and Non-dialysis Dependent Advanced Chronic Kidney Disease

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A13927-A13927

2020

Volltextzugriff (PDF)

Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry

Thrombosis and haemostasis, 2015-11, Vol.114 (5), p.1076-1084

2015

Volltextzugriff (PDF)

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study

Thrombosis and haemostasis, 2015-08, Vol.114 (3), p.645-650

2015

Volltextzugriff (PDF)

Erratum to: Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs)

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015-12, Vol.15 (6), p.451-452

2015

Volltextzugriff (PDF)

59: ANDEXANET ALFA REVERSES ANTICOAGULATION IN FACTOR XA-ASSOCIATED MAJOR BLEEDING IN ANNEXA-4 STUDY

Critical care medicine, 2019-01, Vol.47 (1), p.30-30

2019

Volltextzugriff (PDF)

Abstract T MP57: Are The Recommendations For The Emergency Management Of Acute Ischemic Stroke Patients On Novel Oral Anticoagulants Sufficient?

Stroke (1970), 2014-02, Vol.45 (suppl_1)

2014

Volltextzugriff (PDF)

Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1

European heart journal supplements, 2015-07, Vol.17 (suppl D), p.D21-D28

2015

Volltextzugriff (PDF)

Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1

European heart journal supplements, 2015-07, Vol.17 (suppl D), p.D42-D52

2015

Volltextzugriff (PDF)

Andexanet Alfa for the Management of Acute Major Bleeding Associated with FXa Inhibitors (P5.059)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux: Haemostasis Themed Issue

British journal of clinical pharmacology, 2011, Vol.72 (4), p.715-716

2011

Volltextzugriff (PDF)

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the D resden NOAC registry

British journal of clinical pharmacology, 2014-10, Vol.78 (4), p.908-917

2014

Volltextzugriff (PDF)

Abstract 13021: Comparative Risk of Major Bleeding With Rivaroxaban and Warfarin: Population Based Cohort Study of Unprovoked Venous Thromboembolism

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A13021-A13021

2018

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

KollektionWK Lippincott Williams & Wilkins–Connect here FIRST to enable access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)

Erscheinungsjahr

n.n

Kollektion

Journals@Ovid Full Text
(18)
EZB Free E-Journals
(11)
Ingenta.com
(11)
IngentaConnect Journals
(9)
Single Journals
(6)
Wiley Online Library - AutoHoldings Journals
(4)
MEDLINE
(3)
Wiley Online Library
(3)
Thieme Connect Journals
(3)
Oxford journals
(2)
Oxford Journals 2020 Medicine
(2)
Nexis Uni
(1)
Nature
(1)
Springer Nature - Complete Springer Journals
(1)

9 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE

Abstract 18238: Transition from Vitamin-K-antagonists to New Oral Anticoagulants in Daily Care - First Results of the Prospective NOAC Registry (NCT 01588119)

Anticoagulant therapy for splanchnic vein thrombosis

Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

579 The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis

Abstract 13927: Advanced Age and Preferential Use of Vitamin K Antagonists in Severe Renal Impairment: First Results of the XARENO Registry in Patients With Non-valvular Atrial Fibrillation and Non-dialysis Dependent Advanced Chronic Kidney Disease

Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study

Erratum to: Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs)

59: ANDEXANET ALFA REVERSES ANTICOAGULATION IN FACTOR XA-ASSOCIATED MAJOR BLEEDING IN ANNEXA-4 STUDY

Abstract T MP57: Are The Recommendations For The Emergency Management Of Acute Ischemic Stroke Patients On Novel Oral Anticoagulants Sufficient?

Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1

Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1

Andexanet Alfa for the Management of Acute Major Bleeding Associated with FXa Inhibitors (P5.059)

Erratum to Barco et al. “Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial” (Thromb Haemost 2016; 116: 191-197)

Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux: Haemostasis Themed Issue

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the D resden NOAC registry

Abstract 13021: Comparative Risk of Major Bleeding With Rivaroxaban and Warfarin: Population Based Cohort Study of Unprovoked Venous Thromboembolism

Aktive Filter

Suchergebnisse filtern